S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

First International Summit on Interventional Pharmacoeconomics

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Jul

Today In Oncology

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Integrating Environmental Health Into Pediatric Cancer Care May Improve Outcomes

Emergency Department Cancer Diagnosis Associated With Higher Mortality Across 16 Cancer Types

AMP Recognizes NCI Pathologist With Award for Excellence in Molecular Diagnostics

Defining Functional High-Risk Multiple Myeloma in the Era of Quadruplet Therapy and Autologous Stem Cell Transplant

Long-Term Outcomes With SABR in Primary Kidney Cancer